Drug Profile
Influenza A virus H1N1 vaccine intranasal - BioDiem/Serum Institute of India
Alternative Names: LAIV influenza A vaccine H1N1 - SII; Live-attenuated influenza virus vaccine H1N1; Nasovac; Pandemic influenza A H1N1 - intranasalLatest Information Update: 04 Mar 2014
Price :
$50
*
At a glance
- Originator Institute of Experimental Medicine of the Russian Academy of Medical Sciences
- Developer Serum Institute of India
- Class Influenza A virus H1N1 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Influenza A virus H1N1 subtype
Most Recent Events
- 31 Jul 2010 Launched for Influenza-A virus H1N1 subtype in India (Intranasal)
- 10 Jul 2010 The Serum Institute of India completes a phase II/III trial in Influenza-A virus H1N1 (prevention, in paediatric, adult and elderly volunteers) in India
- 10 Jul 2010 The Serum Institute of India completes a phase I trial in Influenza-A virus H1N1 (prevention, in volunteers) in India